TrivarX Limited (MDBIF)
OTHER OTC:MDBIF
MDBIF Stock Chart & Stats
$0.02
>-$0.01(-69.43%)
At close: 4:00 PM EST
$0.02
>-$0.01(-69.43%)
Day’s Range― - ―
52-Week Range$0.02 - $0.02
Previous CloseN/A
Volume875.00
Average Volume (3M)0.00
Market Cap
$13.80M
Enterprise Value$18.53M
Total Cash (Recent Filing)$1.25M
Total Debt (Recent Filing)$169.03K
Price to Earnings (P/E)―
Beta-0.92
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,153,693,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market Cap1.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-353.28
Enterprise Value/Ebitda-9.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseVery low debt-to-equity (~0.013) and equity of ~A$12.65M provide a durable capital cushion that reduces insolvency and refinancing risk. This structural strength gives the company runway to pursue product development or commercialization over months without immediate debt pressure.
Improving Operating LossesYear-over-year reduction in net loss (from -A$1.24M to -A$0.94M) signals improving cost structure or progress toward scaling operations. A consistent downward trend in losses is a durable indicator management is closing gaps toward profitability, reducing future financing needs if sustained.
Material Reduction In Cash BurnFree cash flow improved materially from -A$3.70M (FY2024) to about -A$0.19M (FY2025), indicating operations are moving toward cash discipline. This structural reduction in burn extends runway, lowers near-term fundraising pressure and improves chances to achieve self-sustaining operations.
Bears Say
No Reported RevenueZero reported revenue in FY2024 and FY2025 means the firm lacks demonstrable product market traction and makes future margin and scalability projections uncertain. Without revenue, durable revenue growth drivers are unproven and the company remains reliant on financing rather than operating cash flow.
Negative Operating And Free Cash FlowContinued negative operating and free cash flow shows the business is not yet self-funding, necessitating external capital to sustain operations. Over a multi-month horizon this raises dilution and funding risk, constraining investment in commercialization and product development.
Persistent Unprofitability And Negative ROENegative returns on equity (~-7.5%) and ongoing net losses indicate retained earnings are not accumulating and shareholder value is eroding. Structurally, persistent unprofitability can pressure future capital raises and limit the company’s ability to fund growth internally over the coming months.
TrivarX Limited News
MDBIF FAQ
What was TrivarX Limited’s price range in the past 12 months?
TrivarX Limited lowest stock price was $0.01 and its highest was $0.02 in the past 12 months.
What is TrivarX Limited’s market cap?
TrivarX Limited’s market cap is $13.80M.
When is TrivarX Limited’s upcoming earnings report date?
TrivarX Limited’s upcoming earnings report date is Aug 27, 2026 which is in 140 days.
How were TrivarX Limited’s earnings last quarter?
TrivarX Limited released its earnings results on Feb 24, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is TrivarX Limited overvalued?
According to Wall Street analysts TrivarX Limited’s price is currently Overvalued.
Does TrivarX Limited pay dividends?
TrivarX Limited does not currently pay dividends.
What is TrivarX Limited’s EPS estimate?
TrivarX Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TrivarX Limited have?
TrivarX Limited has 1,153,693,500 shares outstanding.
What happened to TrivarX Limited’s price movement after its last earnings report?
TrivarX Limited reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of TrivarX Limited?
Currently, no hedge funds are holding shares in MDBIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TrivarX Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-7.84%
Trailing 12-Months
Asset Growth
112.47%
Trailing 12-Months
Company Description
TrivarX Limited
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Mount Lawley, Australia.
Technical Analysis
Resonance Health Ltd
―
Opyl Ltd.
―
MedAdvisor Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―
Ownership Overview
Options Prices
Currently, No data available
---